Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 4/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12413577 | 1.00 | GRIN2B (0.43) | GRIN2BGRM2CHRM5ALDH1A1TSHR | |
| SCHEMBL1002224 | 0.85 | PARP1 (0.40) | PARP1 | |
| SCHEMBL1002222 | 0.85 | PARP1 (0.40) | PARP1 | |
| SCHEMBL2021638 | 0.83 | GRM2 (0.46) | GRIN2BGRM2CHRM5ALDH1A1TSHR | |
| SCHEMBL2026639 | 0.83 | GRM2 (0.47) | GRIN2BGRM2CHRM5ALDH1A1TSHR | |
| SCHEMBL1003527 | 0.82 | GRM2 (0.43) | GRIN2BGRM2CHRM5ALDH1A1METAP2 | |
| SCHEMBL8246819 | 0.81 | GRM2 (0.45) | GRIN2BGRM2CHRM5ALDH1A1TSHR | |
| SCHEMBL2025257 | 0.81 | GRM2 (0.46) | GRIN2BGRM2CHRM5ALDH1A1TSHR | |
| SCHEMBL2026888 | 0.80 | GRM2 (0.47) | GRIN2BGRM2CHRM5ALDH1A1TSHR | |
| SCHEMBL2018587 | 0.80 | GRM2 (0.47) | GRIN2BGRM2CHRM5ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | VAN WAGENEN BRADFORD | 2011-07-07 | — | — | US | disclosed |
| US-7868008-B2 | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | disclosed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | GRM1, GRIN1, GRM2 | GRIN2B 11/4885GRM2 3/4885CHRM5 51/4885 |
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | GRIN2B 11/4885GRM2 3/4885CHRM5 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.